Fenwick has advised Scribe Therapeutics. Latham & Watkins has advised the underwriters. Scribe Therapeutics Inc., a clinical-stage biotechnology company specializing in in vivo CRISPR technologies, has...
Scribe Therapeutics Completes $155.51 Million Initial Public Offering and Private Placement
Remix Therapeutics and Passage Bio Announce Merger and $100 Million Private Placement
Latham & Watkins LLP has advised Remix Therapeutics. Fenwick & West LLP has advised Passage Bio. Cooley LLP has advised Goldman Sachs & Co. LLC, Jefferies...
CareDx Divests Lab Products Business to EuroBio Scientific for $170 Million
Fenwick & West has advised CareDx, Inc.; Kahn Partners LLP has advised EuroBio Scientific S.A. CareDx, Inc. has entered into a definitive agreement to divest its...
Polygon Labs Announces US$250 Million Acquisition of Coinme and Sequence
Wilson Sonsini Goodrich & Rosati and Walkers have advised Polygon Labs; Fenwick & West has advised Coinme. Polygon Labs has entered into definitive agreements to acquire...
MNTN’s $187 Million IPO
Latham & Watkins represented MNTN, Inc. in the offering, and Fenwick & West represented the underwriters. MNTN, Inc. (NYSE: MNTN) announced its initial public offering. The...
GeneDX’s Acquisition of Fabric Genomics
Fenwick & West represented GeneDX in the transaction, and DLA Piper advised Fabric Genomics, Inc. GeneDX (Nasdaq: WGS), a company delivering improved health outcomes through genomic...
CoreWeave’s $1.5 Billion IPO
Fenwick & West represented CoreWeave, Inc. in the offering, and Latham & Watkins represented the underwriters. CoreWeave, Inc. (Nasdaq: CRWV), a developer of a cloud infrastructure...
Rocket Companies’ $1.75 Billion Acquisition of Redfin
Paul, Weiss, Rifkind, Wharton & Garrison advised Rocket Companies on the transaction, and Fenwick & West advised Redfin. Rocket Companies (NYSE: RKT), the Detroit-based fintech platform...
ACELYRIN’s Merger with Alumis
Fenwick & West and Paul Hastings advised ACELYRIN, INC. on the transaction, and Cooley advised Alumis Inc. ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company...
BioAge Labs’ $238 Million Upsized Initial Public Offering
Fenwick & West represented BioAge Labs, Inc. in the offering, and Cooley represented the underwriters. BioAge Labs, Inc. (Nasdaq: BIOA), a clinical-stage biopharmaceutical company developing therapeutic...
Blackstone and Vista Equity Partners’ $8.4 Billion Acquisition of Smartsheet
Fenwick & West is representing Smartsheet on the transaction, while Kirkland & Ellis and Simpson Thacher & Bartlett are representing Blackstone and Vista Equity Partners. Smartsheet...
Eli Lilly’s $3.2 Billion Acquisition of Morphic Holdings
Fenwick & West represented Morphic Holdings, Inc. in the transaction, and Kirkland & Ellis represented Eli Lilly and Company. Eli Lilly and Company (NYSE: LLY) announced...